NEW YORK: Pfizer has entrusted WPP, with Cohn & Wolfe at the helm, to handle global PR responsibilities for three leading products in its cardiovascular franchise, which includes Lipitor, the world?s best-selling drug.
The decision comes two months after Pfizer invited the world?s three largest marketing holding companies - WPP, IPG, and Omnicom - to each assemble their strongest PR teams to pitch for the business. Earlier this month, Omnicom dropped out of the race.
In addition to Lipitor, the account includes Norvasc, a treatment for hypertension and angina, and Caduet, a dual therapy of Lipitor and Norvasc currently awaiting FDA approval.
Check PRWeek.com and the February 2 issue of PRWeek magazine for further updates on this story